Kangstem Biotech Surges 16.58% Amid Umbilical Cord Blood Theme Rally

On January 7, the umbilical cord blood theme showed strong performance, rising by 3.04% compared to the previous day. Among related stocks, Kangstem Biotech is drawing attention as it surged by 16.58% compared to the previous day. Kangstem Biotech is known as a company engaged in the development, manufacturing, and supply of stem cell therapeutics.

[Graph] Major Stock Price Fluctuations in the Umbilical Cord Blood Theme

According to provisional data compiled at 10:51 AM, foreign investors made large net purchases of Kangstem Biotech, buying 61,900 shares.

[Table] Net Buying/Selling Volume by Foreign Investors and Institutions (Unit: 10,000 shares)

According to the analysis by Thinkpool's robo-algorithm RASSI, Kangstem Biotech's quant financial score is 2.67, which is lower than the average of other stocks related to umbilical cord blood in terms of stability, profitability, and growth. This suggests that, from a financial perspective, Kangstem Biotech is not particularly attractive for investment compared to its peers. In contrast, Green Cross ranked first in quant financial scores, with higher growth, stability, and profitability than the average of other stocks.

[Table] Top Financial Scores Within the Theme

* The quant financial score is the result of an analysis by the robo-algorithm based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, and ROE.

* This article was automatically generated in real time by a news automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.